88320
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 8
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.982598691
- umap2_2d
- 1.110155162
- umap1_3d
- 0.043993858
- umap2_3d
- 2.860540135
- umap3_3d
- -1.449656337
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- NOTCH_SIGNALING+0.380
- GLYCOLYSIS+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- TNFA_SIGNALING_VIA_NFKB+0.340
- ANGIOGENESIS+0.330
- MTORC1_SIGNALING+0.330
- HYPOXIA+0.310
- INFLAMMATORY_RESPONSE+0.300
- MYC_TARGETS_V2+0.290
Top 10 suppressed
- PROTEIN_SECRETION-0.230
- PANCREAS_BETA_CELLS-0.220
- SPERMATOGENESIS-0.180
- INTERFERON_ALPHA_RESPONSE-0.160
- KRAS_SIGNALING_DN-0.080
- APICAL_SURFACE-0.040
- BILE_ACID_METABOLISM-0.040
- HEME_METABOLISM-0.040
- KRAS_SIGNALING_UP-0.010
- HEDGEHOG_SIGNALING+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QP6MSKRE | Spinal Cord Ependymoma | — | 0.843 |
| 2 | SRR12475169 | — | — | 0.824 |
| 3 | 81B10E10-884A-46EB-9F28-758D805FB9B1 | — | — | 0.809 |
| 4 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.806 |
| 5 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.804 |
| 6 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.800 |
| 7 | MNG668 | — | — | 0.800 |
| 8 | E24D233D-71BD-4EC2-A671-375917F24E5C | — | — | 0.799 |
| 9 | A462D32E-3A6A-4E00-A4A7-BAF374D6009C | — | — | 0.798 |
| 10 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |